PHILIP-MORRIS-INTL
21.2.2020 15:00:09 CET | Business Wire | Press release
Statement by Dr. Moira Gilchrist BSc (Hons) Pharmacy, PhD Pharmaceutical Sciences, Vice President Strategic & Scientific Communication, Philip Morris International:
“‘You should develop a safer product.’ For decades, that is what governments and the public health community have told the tobacco industry. PMI has invested billions of dollars in science and technology to achieve that precise objective.
“A campaign coordinated by American special interest groups, all of whom are seemingly funded by the same source—Bloomberg Philanthropies—are dedicated to just one mission. Under the guise of promoting public health, they are working to rob adults who smoke of their right to choose scientifically substantiated better alternatives to continued smoking. We have a question for them: Why are they using an elaborate network of organizations to deceive adults who smoke, elected officials, and the public health community? We can only conclude that they are pursuing a disastrous prohibition-only crusade. We urge these groups to: STOP ignoring the rights of hundreds of millions of adults who smoke and who deserve better alternatives; STOP ignoring science and evidence that doesn’t fit with their dogma; and START having a real conversation.
“This dangerous and misguided campaign has provided grants to media for journalism that many people believe is independent. Ultimately, this undermines the goal of harm reduction and confuses adults who smoke about better choices. And ironically, the campaign attacks the only company that has publicly committed to eliminate cigarettes.
“If people who smoke are denied accurate information—or worse yet, are deceived—about less harmful alternatives, the vast majority will simply continue to smoke cigarettes.
“To set the record straight we have addressed all of the allegations made against us by this global campaign on our website: PMI.com . We invite everyone to learn the facts, study our science and arrive at their own conclusions. We have nothing to hide.”
Background
We are moving as fast as we can, but more importantly adults who smoke are voting with their feet and switching as fast as they can.
We have been clear about our objective to end cigarette sales. This is the future of our company; for PMI there is no turning back. We have the determination to make it work.
The proof is in the numbers:
- Smoke-free products are now almost a fifth of our business—up from zero five years ago
- Since 2008, we have invested $7.2 billion to develop and scientifically substantiate smoke-free alternatives
- Nearly 10 million adults have completely stopped smoking cigarettes and switched to our electrically heated tobacco system, which is now available in 52 markets
- Whilst cessation is clearly the best option, our market research across many countries indicates that 80% of adults who smoke want better alternatives
- In 2019, 71 percent of our commercial spend was dedicated to smoke-free products
These facts are the real story.
The question for our critics is this: do they want to make our transformation away from cigarettes slower or faster? Do they want it to make it more difficult for adults who would otherwise continue smoking to choose better products, or less difficult?
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of December 31, 2019, PMI estimates that approximately 9.7 million adult smokers around the world have already stopped smoking and switched to PMI's heat-not-burn product, available for sale in 52 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20200221005254/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing16.9.2026 07:00:00 CEST | Press release
Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121 Restylane Volyme was well tolerated, with no incidences of granulomas. Patient and investigator satisfaction were also high1 These data support Galderma’s aim to expand the availability of the Restylane portfolio in China – a market undergoing significant expansion, and further strengthen Restylane’s vast clinical evidence base2,3 Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its
Nippon Electric Glass’s IR Transmitting Glass “FI-02” Adopted for Heimann Sensor Lens Unit, Enabling a 120° × 68° Field of View16.9.2026 03:00:00 CEST | Press release
Nippon Electric Glass Co., Ltd. (NEG) (TOKYO: 5214), a global leader in specialty glass headquartered in Otsu, Japan, announced that its IR Transmitting Glass (chalcogenide glass) “FI-02” has been adopted for Heimann Sensor GmbH’s wide-angle lens unit for thermal cameras. The lens unit achieves a 120° × 68° field of view, surpassing the previous product’s maximum of 92° × 59°. The adoption marks a significant milestone for FI-02 and showcases how advanced specialty glass can meet the demanding optical and manufacturing requirements of the expanding infrared sensing market. Thermal cameras detect infrared radiation emitted by people or objects and convert it into thermal images. Infrared sensors can detect the locations of people and temperature distributions. They are expected to be used for people detection and monitoring, where privacy considerations are important, and for air-conditioning control, while their use is expanding in healthcare, equipment monitoring, and security. Advanc
Workiva Advances Regulatory Work with AI Innovation15.9.2026 17:00:00 CEST | Press release
Agent Studio anchors AI capabilities unveiled at Amplify 2026 Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, unveiled dozens of new product and platform innovations at Amplify 2026, the company’s annual conference attended by thousands of finance, accounting, sustainability, risk, and compliance leaders. Workiva Debuts Agent Studio Workiva introduced Agent Studio, a landmark platform capability that empowers users to quickly build, customize, and deploy AI agents in Workiva's trusted platform. By combining AI reasoning with Workiva's native platform capabilities, enterprise knowledge, and governed workflows, Agent Studio enables users to automate sophisticated manual business processes without writing any code. Organizations can enrich agents with company-specific knowledge and context, tailor them to their own processes, and schedule automations to execute recurring work. “With Agent Studio, we're putting the power to build in the
Study: Heatwaves Increase Cough Urge, Which Salt Aerosols Reduce15.9.2026 15:15:00 CEST | Press release
New Study Indicates Non-Pharmacological Aerosol May Provide Therapeutic Relief for Respiratory Conditions Provoked by the Atmospheric Aridity Inherent to Heatwaves SC Therapeutics, with University North Carolina, Imperial College London, and Boston University, announced publication on Tuesday in Nature Scientific Reports of results from a multi-institutional study indicating that the aridity inherent in heatwaves increases cough hypersensitivity in human airways by collapsing mucus onto cilia in a manner common to chronic respiratory diseases, such as cystic fibrosis, and asthma. The researchers find that alkaline aerosols of magnesium salts reverse mucosal collapse for several hours, and reduce cough hypersensitivity as reflected in placebo-adjusted suppression of daily cough bout rate (59%, p=0.03) and persistence of suppression post treatment for 1 to 3 weeks in a randomized, double-blind, placebo-controlled study of 10 refractory chronic cough patients. “Paris recorded 5,764 excess
ADM’s Fourth Annual Regenerative Agriculture Report Highlights Growing Resilience Across the Food System15.9.2026 15:00:00 CEST | Press release
2025 programs engaged more than 56,000 farmers across 4.6 million acres in 11 countries ADM (NYSE: ADM), a global leader in innovative solutions from nature, today released its fourth annual regenerative agriculture report, showing how its programs are supporting farmers, strengthening agricultural supply chains and delivering measurable environmental outcomes around the world. “Resilience starts on the farm. By improving and protecting soil health, farmers can be better equipped to adapt to changing conditions and maintain productive operations,” said Greg Morris, SVP and President, Ag Services and Oilseeds, ADM. “That resilience can extend across the value chain, helping strengthen the food system we all depend on.” In 2025, ADM’s regenerative agriculture programs engaged more than 56,000 farmers across approximately 4.6 million acres, 11 countries and 10 crops. Compared with regional benchmarks, the programs resulted in approximately 946,000 metric tons of CO₂e reductions. “ADM view
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
